ALK1/VEGF bi-functional antibody conjugate (Pfizer)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NameALK1/VEGF bi-functional antibody conjugate (Pfizer)

Drug Alias Nameanti-huALK-1-5508

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsVascular endothelial growth factor receptor antagonists

TargetsVascular endothelial growth factor receptorAnaplastic lymphoma kinase

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A